Skip to content
Screener

Bicara Therapeutics BCAX Business Segments — Operating Income (Loss)

Similar metrics at other companies

Target logo
TGTReportable Segment — Operating Income (Loss)
$1.14B-22.9%
Ross Stores logo
ROSTReportable Segment — Operating Income (Loss)
$804.03M+32.6%
Williams-Sonoma logo
WSMReportable Segment — Operating Income (Loss)
$291.69M+0.3%
Samsara logo
IOTReportable Segment — Operating Income (Loss)
$7.2M+122%
ALX
ALXReportable Segment — Operating Income (Loss)
$24.43M-16.8%
The Buckle logo
BKEReportable Segment — Operating Income (Loss)
$59.45M+36.5%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.81B+217%
Enterprise value$1.49B+1,000%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-033429
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Facility costs, IT, office expense and other1,2191,119
Total general and administrative expenses12,7427,455
Total operating expenses60,24241,788
Operating loss(60,242)(41,788)
Interest income4,0835,014
Total other income4,0835,014
Net income before losses(56,159)(36,774)
Income tax expense(52)(72)

Item 1. Financial Statements (Unaudited)

FAQ

What is Bicara Therapeutics's business segments — operating income (loss)?
Bicara Therapeutics (BCAX) reported business segments — operating income (loss) of -$60.24M in Q1 2026.
How has Bicara Therapeutics's business segments — operating income (loss) changed year-over-year?
Bicara Therapeutics's business segments — operating income (loss) decreased by 44.2% year-over-year, from -$41.79M to -$60.24M.
What is the long-term trend for Bicara Therapeutics's business segments — operating income (loss)?
Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — operating income (loss) has grown at a 97.5% compound annual growth rate (CAGR), from -$39.89M to -$155.6M.
What does business segments — operating income (loss) mean?
This metric represents the profit or loss generated by the company's primary business activities, calculated by subtracting total operating expenses from total operating revenues. It serves as a key indicator of the core operational efficiency and the sustainability of the company's research and development-focused business model before accounting for financing or tax impacts.

Ask your AI about Bicara Therapeutics's business segments — operating income (loss).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude